SEPNHIGH SIGNALFINANCIAL10-K

SEPN shows dramatic financial transformation with revenue surging 4,175% to $46M while liabilities exploded 487% to $214.3M, alongside discontinuation of key drug candidate SEP-786.

The massive liability increase of $178M combined with cash declining by half suggests either a major acquisition, debt raise, or significant operational expansion that investors need to understand. The drug discontinuation represents a strategic pivot that could impact the company's development pipeline and future prospects.

Comparing 2026-03-09 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

SEPN underwent a dramatic financial transformation with revenue exploding from $1.1M to $46M while accounts receivable jumped nearly 6,000% to $10.4M, suggesting either a major new revenue stream or business combination. However, total liabilities skyrocketed 487% to $214.3M and cash fell 49% to $120.7M, creating a concerning liquidity picture despite positive operating cash flow of $110.2M. The combination of massive revenue growth, exploding liabilities, and declining cash suggests a transformative event that fundamentally changed the company's financial profile and risk structure.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
+5956.1%
$171K→$10.4M

Receivables surged 5956.1% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Revenue
P&L
+4174.5%
$1.1M→$46.0M

Strong top-line growth of 4174.5% — accelerating demand or successful expansion into new markets.

Current Liabilities
Balance Sheet
+576.6%
$12.8M→$86.9M

Current liabilities surged 576.6% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+486.9%
$36.5M→$214.3M

Liabilities grew 486.9% — significant increase in debt or obligations, assess impact on financial flexibility.

Operating Cash Flow
Cash Flow
+263.3%
-$67.5M→$110.2M

Operating cash flow surged 263.3% — exceptional cash generation, highest quality earnings signal.

Capital Expenditure
Cash Flow
-75.4%
$2.1M→$518K

Capex reduced 75.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

R&D Expense
P&L
+49.4%
$65.3M→$97.6M

R&D investment increased 49.4% — signals commitment to future product development, though near-term margin impact.

Cash & Equivalents
Balance Sheet
-49.3%
$238.2M→$120.7M

Cash declined 49.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Net Income
P&L
+31.9%
-$71.8M→-$48.9M

Net income grew 31.9% — bottom-line growth signals improving overall business health.

Total Assets
Balance Sheet
+30.6%
$456.6M→$596.2M

Asset base grew 30.6% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-27
ADDED
In determining the market value of non-affiliate common stock, shares of the registrant s common stock beneficially owned by officers, directors and affiliates have been excluded.
This determination of affiliate status is not necessarily a conclusive determination for other purposes.
As of March 2, 2026, the registrant had 44,906,374 shares of common stock, $0.001 par value per share, outstanding.
federal trademark filings, including a registered trademark, and possess proprietary trademark rights in our name and logo that we use in connection with the operation of our business.
federal government shutdown or reduced resources, new or increased international tariffs and retaliatory tariffs, trade protection measures, economic sanctions and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts as well as the value of our common stock and our ability to access capital markets; and other risks and uncertainties, including those listed under the section titled Risk Factors in Part I, Item 1A of this Annual Report.
+7 more — sign up free →
REMOVED
The registrant s common stock began trading on the Nasdaq Global Market on October 25, 2024.
As of March 17, 2025, the registrant had 44,442,496 shares of common stock, $0.001 par value per share, outstanding.
federal trademark applications and unregistered trademarks, including our company name and logo, that we use in connection with the operation of our business.
On February 18, 2025, we announced our decision to discontinue the development of SEP-786 and advance a next-generation oral small molecule PTH1R agonist from our PTH1R program.
In completed 28-day preclinical toxicology studies, SEP-786 was generally well-tolerated, without predicted risk of bilirubin elevation.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →